Fiera Capital Corp Trims Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Fiera Capital Corp lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 359,996 shares of the biotechnology company’s stock after selling 22,649 shares during the quarter. Fiera Capital Corp’s holdings in Sarepta Therapeutics were worth $44,960,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $607,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $4,771,000. Securian Asset Management Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $1,187,000. Natixis Advisors LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $1,918,000. Finally, Oppenheimer Asset Management Inc. raised its holdings in Sarepta Therapeutics by 32.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock valued at $467,000 after acquiring an additional 874 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 2.3 %

Sarepta Therapeutics stock traded down $2.74 during midday trading on Friday, hitting $117.68. 532,508 shares of the company were exchanged, compared to its average volume of 1,230,146. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a fifty-two week low of $75.85 and a fifty-two week high of $173.25. The company’s fifty day moving average price is $126.20 and its 200-day moving average price is $132.77. The company has a market cap of $11.22 billion, a PE ratio of 267.61 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, research analysts predict that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Barclays decreased their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Guggenheim increased their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $152.00 to $167.00 in a research report on Thursday. One analyst has rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.